Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2647 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-02-19 (tec.mx)
The knowledge economy: the engine that drives global transformation
Discover how Mexico is moving towards a knowledge economy, promoting innovation and technological development. Be part of this change
Read more
2025-02-12 (kathimerini.gr)
The effort to develop research is collapsing
Two more resignations of members of the National Council of Research, Technology and Innovation became known yesterday, which were accompanied by fire against the Ministry of Development.
Read more
2025-01-30 (thepharma.media)
Sage Therapeutics finally rejected the proposal proposal - Media
Biogen and Sage Therapeutics have been cooperating since 2020, in particular, the development of the postpartum depression Zurzuvae (Zuranolon).
Read more
2025-01-03 (onlarissa.gr)
Small biotechnological pharmaceuticals are gaining ground with treatment approvals in the USA – .GR New News Larissa
The changes in the research and development of new drugs and the emphasis now on cell and gene therapies, bring to the center of interest the
Read more
2024-11-22 (istream.sk)
Breakthrough in the treatment of Alzheimer's disease: When will the revolutionary drug arrive in Slovakia?
The European Medicines Agency (EMA) recently approved a new Alzheimer's drug called Leqembi, developed by Biogen and Eisai. This one
Read more
2024-11-20 (biospace.com)
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
Read more
2024-11-15 (devdiscourse.com)
EU Backs Leqembi: A Breakthrough in Alzheimer's Treatment
The European Union's drugs regulator has recommended approval for Eisai and Biogen's Alzheimer's drug Leqembi. This marks a potential first treatment approval in the EU for early Alzheimer's, focusing on patients without the ApoE4 gene variant.
Read more
2024-11-14 (lvz.de)
Breakthrough in Alzheimer's disease: Lecanemab could soon become the first approved therapy in the EU
In Germany alone, more than a million people live with Alzheimer's disease. The drug Lecanemab could help some of them. The EU Medicines Agency now recommends the drug for at least one group of patients.
Read more
2024-11-06 (news-medical.net)
Lupus Research Alliance announces 33 studies to be presented at ACR Convergence 2024
The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that a total of 33 studies, funded by the organization or supported by its clinical research affiliate Lupus Therapeutics, will be presented at ACR Convergence 2024.
Read more